and on call. this everyone quarter CooperSurgical. Companies welcome first with CooperVision performances fiscal Cooper year XXXX note We conference Thank positive operational both strong you, at Kim, and started a to
organic growth. we reported revenues of quarterly quarter revenue CooperVision, double consecutive our record and eighth digit For
double organic CooperSurgical, For ninth revenue consecutive results of its including posted reporting quarter digit strong we growth. fertility
in year start solid balancing strength activity efficiencies This will yielding by revenues to operational and expected. investment driven deliver exactly faster with management expectations the the continue than and to results. wanted exceeded Earnings is we operational activities prudent investment how
XX% the revenues posted organically. million CooperVision’s and revenue organically led products revenues quarterly $XXX daily broad all-time up million. quarterly and Consolidated and up CooperSurgical’s based record share to management $X.XX. our reached growth with per growth was was of high of many in hydrogel of CooperVision silicone CooperSurgical by strength XX% $XXX million Moving Non-GAAP myopia numbers. earnings were $XXX posted an areas. portfolio
QX was launches, product was and XX%. offerings organic percentages in reporting grew key The XX% revenue expanded market and grew customized Pac flexibility ranges, This product an through and on basis, diversified. our Asia leading growth driven in accounts. by Americas performance CooperVision X%, For strong growth grew and EMEA new
Regarding product hydrogel silicone XX% especially lenses from details, with daily grew MyDay. strong growth
lenses be a growth spheres clarity the to offer of the the portfolio and we Daily hydrogel wide contact lens available silicone continue and torques and for industry MyDay in of broadest range with main multifocals. driver
growth. week of two and Vitality Biofinity quarter and monthly hydrogel lenses silicone Avaira another As X% solid reported
During the product remain extremely news we busy.
Asia and MyDay we to and growth product available taking incredibly strong the we becomes rollout going customers as EMEA more in remains outstanding and Our practitioners multifocal well continue expect and readily Feedback is continue Pac. share. from
sphere well daily expanded wearing range halo enjoy the the ever. over MyDay a the and widest XXXX be in first U.S. lens and rollout which freedom also activity range launching positive All the by having performing toric quarter. of monthly Canada has is expansion to parameter the toric to going SKUs and also the toric is time we'll this MyDay torque for EMEA door a its With weeks opening contact many this in the daily well. two wears impact margin and the market a in on is our MyDay wide Our
U.S., on eye same MyDay alleviate digital strain resulting Biofinity to lens MyDay the of a lastly, uses that day impacts premium franchise. the Studies And and I'm more now seven excited as this innovative digital the spending national boost than announce technology started uncomfortable. the eyestrain. on show ceiling Energys in adults Energys are hours we to screens, of rollout in
our the dedicated this survey and to get practitioners MyDay boost developing customers perfect technologically this shows products and come. daily for MyDay remain its that offering. and fatigue. eye is exciting technology with years solution All activity out technology superior to to this to we and is are work Energys, address excited digital clearly And many a rolling
daily price Clarity way allowing the Clarity mass performing into Lastly, utilizing franchise to eye great segment, silicone space. well. the market practitioners daily care Its is a point wares to is continue the within hydrogel bring as
multifocal torics, of range Demand outside offerings. biofinity Moving strong and led remains dailies. by extended our for
of multifocals. the vitality, to Pac. is constrained a high order some our areas, quarter be these especially the significant we up torics to our But of to as And toric continue in extremely and ramp nice a in allowing such lastly, address around made demand. range We Asia capacity with us extended had very continued demand products especially facilities manufacturing
on line posted with sales in keeps was $XXX of in revenues this year. management, MiSight with Moving $XXX and reach to million of XX% we $XX up million XX%. our up us track million expectations This goal to to Myopia
offices activity control numerous expanded expanding availability CooperVision progress comfortable accelerating a We're as their to continuing effect our with management. more And our practice other actively making and in accounts Regarding great on MiSight, we're we're optical their increased see efforts. use launching halo customers range MiSight numerous Myopia R&D become parameter key positive of with lenses. seeing sitting
and the eye care as eye risk Myopia associated and within health retinal This the control a for of is extensive is by of care management such and Myopia community become of reduce with longtime standard cataracts, backed as clinical help the problems MiSight is Myopia first critical the the macular lens FDA product detachment, contact degeneration. approved only data. differentiator proactive to
done that efforts. In million we're great major bottles contact equivalent than CooperVision work in announced of I This team the our the sustainability and incredibly has from to mention that entering net by eye the program more wearers milestone the a plastic reached success. environmental XXX and lens the with received Finally, initiative January, its oceans. of we prevention has our of neutrality plastic care been professionals extremely proud well want
by on trend needing of XX%. by population XXXX roughly year of up expect global from year vision the It's And contact estimated To macro more roughly faster X% today. the a at nearsightedness the CooperVision market to the grew correction. growing growth finish have XX% myopia people or calendar we another robust CooperVision, XXXX, supported with lens XXXX, will in XX% be
hydrogel when multifocals, This time, ongoing products and silicon is driven by with shift greater including variety to and combined the focus a the torics value on screen of higher higher increasing pricing. dailies, factors and as such
strong business data. expect for our robust remain the years expect We management of launches, new to ongoing leading growing we industry. a Myopia product fit product fast And and growth many portfolio, leader with
and its sales to product to business strong year, of Moving of base with for double ninth start fertility organic the fiscal XX% consecutive this excellent around organically Success results the was throughout $XXX portfolio quarter was digit posted the growth. world. CooperSurgical, million up an broad our
and very stands beginning countries macro a with growth and in exciting woman's supporting There several drivers market industry The in U.S. the age fertility space now to global contributing for The and old strong age significant remains years women delaying trends developed key are potential. childbirth. need within first factor fertility term multiple long this at a other the with record XX birth a assistance. is average
XX% include and It's awareness, offerings, improved access coverage, through numbers measures, benefit technology are babies assisted female patient challenges increasing to infertility Other and and have over treatment, that product for fertility increasing are estimated improvements of born reproductive challenges. improving couples growth growing. these that fertility age annually fertility XXX,XXX both male and roughly drivers
forecast billion XX% of we to many sales a that's the growth broader space, to $X X% Within fertility come. roughly annual for in and compete in we market years
Our and accounts. commercial positioning is the solid with key footprint a in portfolio excellent on industry, the broadest strength
our especially services capital and Demand building expanding genetic in portfolio, equipment infrastructure very reproductive in testing. we're products by our We're and this investing market. within geographically. our consumables, and to product high and strong, people keep accounts, we key the investing also which remains includes And need our growth required team so delivering in
and work this OB/GYN posted PARAGARD ongoing Moving And and managing to supply medical products. XX% This team organically. products, storage, is I'm several of a we $XXX strength with million we're the Within proud hard of demand core in devices strong sales having OB/GYN great which challenges. stem devices, grew chain includes with seen Surgical our XX%, cell Office success job doing up medical and of
PARAGARD lastly, price this improving in year to but grew for business grew We've cell organically. of we're implemented happy We'll to natural buying stem roughly traction. offset that it's at the this XX% good And a quarter. report driven end business to And year start. a of our storage a increase off nice seeing see over to the the QX, a from owned by X% just get now. I'm activity X%
and the is we business synergies in part of a The as transaction the occurring position. are expected good
an I'm in of focus report investment happy part and cells. recently efforts we Tegan, importance this our with off our preserving stem ongoing marketing exciting leading campaign of newborn latest As and the around space educational Chrissie kicked to activity
see year. this The very media I'm been to through progresses excited it early value reaction to delivers positive and campaign the has social and how
shows and CooperSurgical, is fantastic love really every using is. our of. a conclude business I that proud truly mention that something products. CooperSurgical baby meaningful born a just CooperSurgical it I Worldwide minute To want and to now what I'm
this start let So year. how is we to say this wanted me summarize, again fiscal exactly to
strong, excellent, executing is to was performance operational sustainable our momentum term growth. on drive investments Our our long we're and
with turn the Brian. call let me over to And that,